Two cases of chronic hepatitis B with emergence of lamivudine-resistant virus during long-term therapy

Shin Ichi Fujioka, Hiroyuki Shimomura, Kozo Fujio, Fusao Ikeda, Masanobu Miyake, Yasushi Ishii, Mamoru Itoh, Kosaku Sakaguchi, Takao Tsuji

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Lamivudine is a potent antiviral drug for chronic hepatitis B, however the emergence of mutant virus resistant to lamivudine has been reported in patients with long-term administration of this drug. Here we report two patients with chronic hepatitis B treated with 48- and 52-weeks administration of lamivudine whose serum hepatitis B virus (HBV) DNA became positive during therapy. The amino acid sequence of the polymerase region of HBV from these patients revealed a YI/VDD mutation of the YMDD motif and a 223Leu to Met mutation, which were reported previously in immune suppressed patients during long-term lamivudine therapy for hepatitis B. After the cessation of therapy, serum HBV-DNA returned to wild-type immediately. Emergence of mutant virus resistant to lamivudine should be monitored during long-term lamivudine therapy.

Original languageEnglish
Pages (from-to)97-104
Number of pages8
JournalHepatology Research
Volume13
Issue number2
Publication statusPublished - Jan 1999

Fingerprint

Lamivudine
Chronic Hepatitis B
Viruses
Hepatitis B virus
Therapeutics
Mutation
DNA
Hepatitis B
Serum
Antiviral Agents
Amino Acid Sequence
Pharmaceutical Preparations

Keywords

  • Antiviral therapy
  • Hepatitis B virus
  • Hronic hepatitis
  • Lamivudine
  • Mutation

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Fujioka, S. I., Shimomura, H., Fujio, K., Ikeda, F., Miyake, M., Ishii, Y., ... Tsuji, T. (1999). Two cases of chronic hepatitis B with emergence of lamivudine-resistant virus during long-term therapy. Hepatology Research, 13(2), 97-104.

Two cases of chronic hepatitis B with emergence of lamivudine-resistant virus during long-term therapy. / Fujioka, Shin Ichi; Shimomura, Hiroyuki; Fujio, Kozo; Ikeda, Fusao; Miyake, Masanobu; Ishii, Yasushi; Itoh, Mamoru; Sakaguchi, Kosaku; Tsuji, Takao.

In: Hepatology Research, Vol. 13, No. 2, 01.1999, p. 97-104.

Research output: Contribution to journalArticle

Fujioka, SI, Shimomura, H, Fujio, K, Ikeda, F, Miyake, M, Ishii, Y, Itoh, M, Sakaguchi, K & Tsuji, T 1999, 'Two cases of chronic hepatitis B with emergence of lamivudine-resistant virus during long-term therapy', Hepatology Research, vol. 13, no. 2, pp. 97-104.
Fujioka, Shin Ichi ; Shimomura, Hiroyuki ; Fujio, Kozo ; Ikeda, Fusao ; Miyake, Masanobu ; Ishii, Yasushi ; Itoh, Mamoru ; Sakaguchi, Kosaku ; Tsuji, Takao. / Two cases of chronic hepatitis B with emergence of lamivudine-resistant virus during long-term therapy. In: Hepatology Research. 1999 ; Vol. 13, No. 2. pp. 97-104.
@article{56c4055325274c5b8d69c9fb2e214332,
title = "Two cases of chronic hepatitis B with emergence of lamivudine-resistant virus during long-term therapy",
abstract = "Lamivudine is a potent antiviral drug for chronic hepatitis B, however the emergence of mutant virus resistant to lamivudine has been reported in patients with long-term administration of this drug. Here we report two patients with chronic hepatitis B treated with 48- and 52-weeks administration of lamivudine whose serum hepatitis B virus (HBV) DNA became positive during therapy. The amino acid sequence of the polymerase region of HBV from these patients revealed a YI/VDD mutation of the YMDD motif and a 223Leu to Met mutation, which were reported previously in immune suppressed patients during long-term lamivudine therapy for hepatitis B. After the cessation of therapy, serum HBV-DNA returned to wild-type immediately. Emergence of mutant virus resistant to lamivudine should be monitored during long-term lamivudine therapy.",
keywords = "Antiviral therapy, Hepatitis B virus, Hronic hepatitis, Lamivudine, Mutation",
author = "Fujioka, {Shin Ichi} and Hiroyuki Shimomura and Kozo Fujio and Fusao Ikeda and Masanobu Miyake and Yasushi Ishii and Mamoru Itoh and Kosaku Sakaguchi and Takao Tsuji",
year = "1999",
month = "1",
language = "English",
volume = "13",
pages = "97--104",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Two cases of chronic hepatitis B with emergence of lamivudine-resistant virus during long-term therapy

AU - Fujioka, Shin Ichi

AU - Shimomura, Hiroyuki

AU - Fujio, Kozo

AU - Ikeda, Fusao

AU - Miyake, Masanobu

AU - Ishii, Yasushi

AU - Itoh, Mamoru

AU - Sakaguchi, Kosaku

AU - Tsuji, Takao

PY - 1999/1

Y1 - 1999/1

N2 - Lamivudine is a potent antiviral drug for chronic hepatitis B, however the emergence of mutant virus resistant to lamivudine has been reported in patients with long-term administration of this drug. Here we report two patients with chronic hepatitis B treated with 48- and 52-weeks administration of lamivudine whose serum hepatitis B virus (HBV) DNA became positive during therapy. The amino acid sequence of the polymerase region of HBV from these patients revealed a YI/VDD mutation of the YMDD motif and a 223Leu to Met mutation, which were reported previously in immune suppressed patients during long-term lamivudine therapy for hepatitis B. After the cessation of therapy, serum HBV-DNA returned to wild-type immediately. Emergence of mutant virus resistant to lamivudine should be monitored during long-term lamivudine therapy.

AB - Lamivudine is a potent antiviral drug for chronic hepatitis B, however the emergence of mutant virus resistant to lamivudine has been reported in patients with long-term administration of this drug. Here we report two patients with chronic hepatitis B treated with 48- and 52-weeks administration of lamivudine whose serum hepatitis B virus (HBV) DNA became positive during therapy. The amino acid sequence of the polymerase region of HBV from these patients revealed a YI/VDD mutation of the YMDD motif and a 223Leu to Met mutation, which were reported previously in immune suppressed patients during long-term lamivudine therapy for hepatitis B. After the cessation of therapy, serum HBV-DNA returned to wild-type immediately. Emergence of mutant virus resistant to lamivudine should be monitored during long-term lamivudine therapy.

KW - Antiviral therapy

KW - Hepatitis B virus

KW - Hronic hepatitis

KW - Lamivudine

KW - Mutation

UR - http://www.scopus.com/inward/record.url?scp=0032938009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032938009&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 97

EP - 104

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 2

ER -